Drug Trial Radar · NCT00262067
A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)
Last checked: Nov 19, 2026Latest source record: Dec 13, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,237
Actual
Start
Dec 2005
Primary completion
Jul 2008
Study completion Dec 2013
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 6, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, multicenter, randomized, placebo-controlled trial designed to evaluate the efficacy and safety of bevacizumab in combination with chemotherapy compared with chemotherapy alone in subjects with previously untreated metastatic breast cancer.
Conditions
- Metastatic Breast Cancer
Interventions
BevacizumabDrug
Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months. The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study. The initial dose was delivered over 90±10 minutes. If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes. If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.
PlaceboDrug
Placebo consisted of the vehicle for bevacizumab without the antibody.
ChemotherapyDrug
The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles. Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle 1. Docetaxel 75-100 mg/m\^2 IV 2. Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle 1. 5-fluorouracil 500 mg/m\^2 IV + epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV 2. 5-fluorouracil 500 mg/m\^2 IV + doxorubicin 50 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV 3. Doxorubicin 50-60 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV 4. Epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV Capecitabine: 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)Time frame: Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
Locations
92 sites in 22 countries. Site status is shown where the registry gives one.
Site not named
Fullerton, California
Site not named
Santa Barbara, California
Site not named
Iowa City, Iowa
Site not named
Sioux City, Iowa
Site not named
Wichita, Kansas
Site not named
Geelong, Australia
Site not named
Malvern, Australia
Site not named
Melbourne, Australia
Site not named
Perth, Australia
Site not named
Southport, Australia
Site not named
Wahroonga, Australia
Site not named
Waratah, Australia
Site not named
Wollongong, Australia
Site not named
Porto Alegre, Brazil
Site not named
Rio de Janeiro, Brazil
Site not named
Salvador, Brazil
Site not named
Santo André, Brazil
Site not named
São Paulo, Brazil
Site not named
Winnipeg, Manitoba, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Marseille, France
Site not named
Paris, France
Site not named
Reims, France
Site not named
Saint-Herblain, France
Site not named
Strasbourg, France
Site not named
Athens, Greece
Site not named
Chania, Greece
Site not named
Heraklion, Greece
Site not named
Pátrai, Greece
Site not named
Thessaloniki, Greece
Site not named
Guatemala City, Guatemala
Site not named
Acapulco, Mexico
Site not named
Aguascalientes, Mexico
Site not named
Mérida, Mexico
Site not named
Monterrey, Mexico
Site not named
Monterrey, Mexico
Site not named
Amstelveen, Netherlands
Site not named
Apeldoorn, Netherlands
Site not named
Delft, Netherlands
Showing 40 of 92 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.